Andrew Scarfe

2.8k total citations
21 papers, 889 citations indexed

About

Andrew Scarfe is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Andrew Scarfe has authored 21 papers receiving a total of 889 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 4 papers in Pathology and Forensic Medicine. Recurrent topics in Andrew Scarfe's work include Gastric Cancer Management and Outcomes (10 papers), Colorectal Cancer Screening and Detection (7 papers) and Colorectal Cancer Treatments and Studies (6 papers). Andrew Scarfe is often cited by papers focused on Gastric Cancer Management and Outcomes (10 papers), Colorectal Cancer Screening and Detection (7 papers) and Colorectal Cancer Treatments and Studies (6 papers). Andrew Scarfe collaborates with scholars based in Canada, United States and United Kingdom. Andrew Scarfe's co-authors include Karen Mulder, Charles Butts, Michael B. Sawyer, Carla M. Prado, Tony Reiman, Linda J. McCargar, Marina Mourtzakis, Vickie E. Baracos, Marcy Winget and Yutaka Yasui and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Clinical Cancer Research.

In The Last Decade

Andrew Scarfe

21 papers receiving 883 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Andrew Scarfe Canada 12 452 392 203 178 159 21 889
Haa‐Na Song South Korea 16 361 0.8× 201 0.5× 282 1.4× 87 0.5× 173 1.1× 47 815
Matilda Holm Finland 8 200 0.4× 440 1.1× 148 0.7× 91 0.5× 171 1.1× 17 842
Trevor A. Jolly United States 14 460 1.0× 314 0.8× 252 1.2× 378 2.1× 69 0.4× 32 953
Sandrine Lavau‐Denès France 15 338 0.7× 172 0.4× 183 0.9× 72 0.4× 97 0.6× 33 677
Øystein Fløtten Norway 14 626 1.4× 336 0.9× 528 2.6× 195 1.1× 80 0.5× 33 1.1k
Hoon‐Gu Kim South Korea 18 321 0.7× 185 0.5× 192 0.9× 84 0.5× 76 0.5× 42 713
Ángel Segura Spain 15 462 1.0× 182 0.5× 125 0.6× 80 0.4× 143 0.9× 45 881
Shani Alston United States 8 233 0.5× 346 0.9× 145 0.7× 328 1.8× 64 0.4× 13 661
Lorenzo Dottorini Italy 13 330 0.7× 167 0.4× 143 0.7× 80 0.4× 61 0.4× 42 664
Santi Barbera Italy 10 632 1.4× 106 0.3× 456 2.2× 148 0.8× 113 0.7× 17 978

Countries citing papers authored by Andrew Scarfe

Since Specialization
Citations

This map shows the geographic impact of Andrew Scarfe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Scarfe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Scarfe more than expected).

Fields of papers citing papers by Andrew Scarfe

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Scarfe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Scarfe. The network helps show where Andrew Scarfe may publish in the future.

Co-authorship network of co-authors of Andrew Scarfe

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Scarfe. A scholar is included among the top collaborators of Andrew Scarfe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Scarfe. Andrew Scarfe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Abraham, Aswin, Kurian Joseph, Jennifer L. Spratlin, et al.. (2022). Does Loosening the Inclusion Criteria of the CROSS Trial Impact Outcomes in the Curative-Intent Trimodality Treatment of Oesophageal and Gastroesophageal Cancer Patients?. Clinical Oncology. 34(9). e369–e376. 5 indexed citations
2.
Abdel‐Rahman, Omar, Patricia A. Tang, Sunita Ghosh, & Andrew Scarfe. (2022). Patterns of emergency department visits preceding colorectal cancer diagnosis: a population-based study. Journal of Comparative Effectiveness Research. 11(5). 311–318. 2 indexed citations
3.
Hayward, Jake, et al.. (2016). Script-theory virtual case: A novel tool for education and research. Medical Teacher. 38(11). 1130–1138. 16 indexed citations
4.
Chu, Michael P., J. Randolph Hecht, Dennis J. Slamon, et al.. (2016). Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer. JAMA Oncology. 3(6). 767–767. 75 indexed citations
5.
Sawyer, Michael B., Edith Pituskin, Sambasivarao Damaraju, et al.. (2015). A Uridine Glucuronosyltransferase 2B7 Polymorphism Predicts Epirubicin Clearance and Outcomes in Early-Stage Breast Cancer. Clinical Breast Cancer. 16(2). 139–144.e3. 17 indexed citations
6.
Hecht, J. Randolph, Dennis J. Slamon, Kathryn King, et al.. (2014). Proton Pump Inhibitor (Ppis) Therapy May Impair Capecitabine (Cape) Efficacy in Metastatic Gastroesophageal Cancer (Gec), Results from the Trio-013/Logic Trial. Annals of Oncology. 25. iv211–iv211. 2 indexed citations
7.
Li, Xue, Andrew Scarfe, Karen King, et al.. (2013). Timeliness of cancer care from diagnosis to treatment: a comparison between patients with breast, colon, rectal or lung cancer. International Journal for Quality in Health Care. 25(2). 197–204. 30 indexed citations
8.
Scarfe, Andrew, et al.. (2012). Reasons physicians do not recommend and patients refuse adjuvant chemotherapy for stage III colon cancer: a population based chart review. BMC Research Notes. 5(1). 269–269. 44 indexed citations
9.
Lima, Isac, Yutaka Yasui, Andrew Scarfe, & Marcy Winget. (2011). Association between receipt and timing of adjuvant chemotherapy and survival for patients with stage III colon cancer in Alberta, Canada. Cancer. 117(16). 3833–3840. 57 indexed citations
10.
Mulder, Karen, Andrew Scarfe, Neil Chua, & Jennifer L. Spratlin. (2011). The role of bevacizumab in colorectal cancer: understanding its benefits and limitations. Expert Opinion on Biological Therapy. 11(3). 405–413. 31 indexed citations
11.
Butts, Charles, et al.. (2011). Utilization of oncology services and receipt of treatment: a comparison between patients with breast, colon, rectal, or lung cancer. Annals of Oncology. 22(8). 1902–1909. 12 indexed citations
12.
Yasui, Yutaka, et al.. (2011). Adherence to Treatment Guidelines in Stage II/III Rectal Cancer in Alberta, Canada. Clinical Oncology. 24(1). e9–e17. 20 indexed citations
13.
Winget, Marcy, Shakhawat Hossain, Yutaka Yasui, & Andrew Scarfe. (2010). Characteristics of patients with stage III colon adenocarcinoma who fail to receive guideline‐recommended treatment. Cancer. 116(20). 4849–4856. 50 indexed citations
14.
Mulder, Karen, Sheryl Koski, Andrew Scarfe, et al.. (2010). Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future. Oncotarget. 1(7). 515–529. 11 indexed citations
15.
Chen, Yiqun, et al.. (2009). Survival of metastatic colorectal cancer patients treated with chemotherapy in Alberta (1995–2004). Supportive Care in Cancer. 18(2). 217–224. 3 indexed citations
16.
Sawyer, Michael B., Edith Pituskin, Vijaya L. Damaraju, et al.. (2009). Uridine glucuronosyltransferase 2B7 pharmacogenetics predicts epirubicin clearance and myelosuppression. Journal of Clinical Oncology. 27(15_suppl). 2504–2504. 3 indexed citations
17.
Prado, Carla M., Vickie E. Baracos, Linda J. McCargar, et al.. (2007). Body Composition as an Independent Determinant of 5-Fluorouracil–Based Chemotherapy Toxicity. Clinical Cancer Research. 13(11). 3264–3268. 488 indexed citations
18.
Sawyer, Michael B., Andrew Scarfe, Vijaya L. Damaraju, et al.. (2006). Uridine glucuronosyltransferase 2B7 polymorphisms and epirubicin pharmacokinetics. Journal of Clinical Oncology. 24(18_suppl). 13071–13071. 1 indexed citations
19.
Mackey, John R., Katia Tonkin, Sheryl Koski, et al.. (2004). Final Results of a Phase II Clinical Trial of Weekly Docetaxel in Combination with Capecitabine in Anthracycline-Pretreated Metastatic Breast Cancer. Clinical Breast Cancer. 5(4). 287–292. 15 indexed citations
20.
Mulder, Karen, Andrew Scarfe, Sheryl Koski, et al.. (2004). A prospective pharmacogenetic study of 5FU/LV in high-risk stage II and III colon cancer patients. Journal of Clinical Oncology. 22(14_suppl). 2067–2067. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Haa‐Na Song Breakdown of academic impact, for papers by Matilda Holm Breakdown of academic impact, for papers by Trevor A. Jolly Breakdown of academic impact, for papers by Sandrine Lavau‐Denès Breakdown of academic impact, for papers by Øystein Fløtten Breakdown of academic impact, for papers by Hoon‐Gu Kim Breakdown of academic impact, for papers by Ángel Segura Breakdown of academic impact, for papers by Shani Alston Breakdown of academic impact, for papers by Lorenzo Dottorini Breakdown of academic impact, for papers by Santi Barbera
Rankless by CCL
2026